MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
Rigel Pharmaceuticals Revenue 2011-2026 | RIGL
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Rigel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 294 M | 179 M | 117 M | 120 M | 149 M | 109 M | 59.3 M | 44.5 M | 4.48 M | 20.4 M | 28.9 M | 8.25 M | 7.15 M | 2.25 M | 4.75 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 294 M | 2.25 M | 76.6 M |
Quarterly Revenue Rigel Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 69.5 M | 102 M | 53.3 M | 55.3 M | 36.8 M | 29.5 M | 28.1 M | 26.9 M | 26.1 M | - | 22.4 M | 29.8 M | 16.7 M | - | 21.5 M | 26.3 M | 81 M | 18.4 M | 18.4 M | 16 M | 55.8 M | 15.4 M | 20.9 M | 10.4 M | 12.6 M | 37.9 M | 4.86 M | 1.79 M | - | - | 900 K | 3.58 M | 3.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 102 M | 900 K | 29.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.62 | -1.09 % | $ 8.71 B |  Australia |
 |
BioNTech SE
BNTX
|
482 M | $ 98.41 | 1.77 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
330 M | $ 4.71 | 4.9 % | $ 760 M |  Britain |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Aligos Therapeutics
ALGS
|
2.19 M | $ 8.74 | 0.23 % | $ 86.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 21.38 | 0.09 % | $ 999 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
236 M | $ 1.56 | 6.12 % | $ 401 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.15 | -0.95 % | $ 444 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 25.09 | 4.02 % | $ 3.19 B | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.48 | 0.68 % | $ 394 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Evogene Ltd.
EVGN
|
3.85 M | $ 0.82 | 0.02 % | $ 27.9 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | USA |
 |
AstraZeneca PLC
AZN
|
58.7 B | - | - | $ 96.9 B | Britain |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Cabaletta Bio
CABA
|
0.006 | $ 3.26 | 1.87 % | $ 328 M | USA |
 |
Cidara Therapeutics
CDTX
|
1.28 M | - | - | $ 1.41 B | USA |
 |
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |